SCHEDULE 13G/A: Perceptive Advisors Discloses 8.8% Stake in Amylyx Pharmaceuticals
Beneficial Ownership Report
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a collective beneficial ownership of 8.8% in Amylyx Pharmaceuticals, Inc.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
- The Reporting Persons collectively beneficially own 7,874,348 shares of Amylyx Pharmaceuticals, Inc. Common Stock.
- This ownership represents 8.8% of the Issuer's outstanding Common Stock.
- The percentage is based on 89,141,087 shares of Common Stock outstanding as of April 28, 2025, as reported in Amylyx's Form 10-Q filed on May 8, 2025.
- Perceptive Advisors serves as the investment manager to the Master Fund, and Mr. Edelman is the managing member of Perceptive Advisors.
- All Reporting Persons share both voting and dispositive power over the 7,874,348 shares.
Sentiment
Score: 6
Explanation: The disclosure of a significant passive stake by a reputable institutional investor like Perceptive Advisors is generally viewed as a positive signal of confidence in the company, though the filing itself is purely factual and does not contain forward-looking statements or performance data.
Positives
- A significant stake (8.8%) held by a prominent institutional investor like Perceptive Advisors may signal confidence in Amylyx Pharmaceuticals' future prospects.
- The filing indicates a passive investment strategy, as Schedule 13G is typically used by investors who do not intend to influence control of the issuer.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Perceptive Advisors LLC serves as the investment manager to Perceptive Life Sciences Master Fund, Ltd., which directly holds the shares.
- Joseph Edelman is the managing member of Perceptive Advisors LLC, establishing a control relationship among the reporting persons regarding the beneficial ownership.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional shareholder, which can influence investor sentiment and potentially provide a floor for the stock price due to a large, passive holder.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement |
| 04/28/2025 | Date as of which 89,141,087 shares of Common Stock were outstanding |
| 05/08/2025 | Date Amylyx Pharmaceuticals, Inc. filed its Quarterly Report on Form 10-Q |
| 05/15/2025 | Date of signing of the Schedule 13G filing |
Keywords
Amylyx Pharmaceuticals, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, beneficial ownership, institutional investor, common stock, AMYLX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.